Document Detail


The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
MedLine Citation:
PMID:  14745084     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized, blinded, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and acute symptomatic effects of CEP-1347 in 30 patients with Parkinson's disease (PD). In this short-term study, CEP-1347 was safe and well tolerated. It had no acute effect on parkinsonian symptoms or levodopa pharmacokinetics, making it well suited for larger and longer studies of its potential to modify the course of PD.
Authors:
Related Documents :
6402914 - Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial.
23014254 - Descriptive analysis of resistance exercise and metabolic syndrome.
1281624 - Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in ca...
6214914 - Double-blind comparison of diltiazem and placebo in the treatment of exercise-inducible...
1483444 - Glucocorticoid response to exercise as measured by serum and salivary cortisol.
6369064 - Metabolic bases of excess post-exercise oxygen consumption: a review.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurology     Volume:  62     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-01-27     Completed Date:  2005-01-14     Revised Date:  2008-06-28    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  330-2     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antiparkinson Agents / adverse effects,  blood,  pharmacokinetics,  therapeutic use*
Area Under Curve
Carbazoles / adverse effects,  blood,  pharmacokinetics,  therapeutic use*
Diarrhea / chemically induced
Double-Blind Method
Female
Humans
Indoles / adverse effects,  blood,  pharmacokinetics,  therapeutic use*
Levodopa / therapeutic use
Male
Middle Aged
Parkinson Disease / blood,  drug therapy*,  enzymology
Protein Kinase Inhibitors / adverse effects,  blood,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Carbazoles; 0/Indoles; 0/Levodopa; 0/Protein Kinase Inhibitors; 156177-65-0/3,9-bis((ethylthio)methyl)-K-252a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spinocerebellar ataxia type 5: clinical and molecular genetic features of a German kindred.
Next Document:  Effects of nitric oxide on proprioceptive signaling.